Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Purpura

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    120 result(s) found for: Purpura. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2005-000859-15 Sponsor Protocol Number: ML 18542 Start Date*: 2005-04-14
    Sponsor Name:ROCHE
    Full Title: Randomized prospective study comparing dexamethasone and dexamethasone plus rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP) in adults.
    Medical condition: Front-line treatment of adult ITP
    Disease: Version SOC Term Classification Code Term Level
    6.1 10021245 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000172-13 Sponsor Protocol Number: 20030213 Start Date*: 2008-08-20
    Sponsor Name:Amgen Inc.
    Full Title: An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of AMG 531 in Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura ( ITP)
    Medical condition: Thrombocytopenia in subjects with Immune Thrombocytopenic Purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) AT (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000638-37 Sponsor Protocol Number: 20040209 Start Date*: 2008-02-28
    Sponsor Name:Amgen Inc.
    Full Title: An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
    Medical condition: Immune (Idiopathic) Thrombocytopenic Purpura
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed) BE (Completed) AT (Completed) IE (Completed) GB (Completed) IT (Completed) ES (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-018794-38 Sponsor Protocol Number: RTXTTP2010 Start Date*: 2010-02-23
    Sponsor Name:FONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
    Full Title: EVALUATION OF CLINICAL RESPONSE TO RITUXIMAB TREATMENT IN PATIENTS WITH ACQUIRED AUTOIMMUNE RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
    Medical condition: THROMBOTIC THROMBOCYTOPENIC PURPURA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037562 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019987-35 Sponsor Protocol Number: 20080435 Start Date*: 2010-07-23
    Sponsor Name:Amgen Inc
    Full Title: A Phase 2, Interventional, Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects with Immune Thrombocytopenia Purpura Receiving Romiplostim.
    Medical condition: Adult immune thrombocytopenic purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021245 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) GB (Completed) ES (Completed) FR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-003552-35 Sponsor Protocol Number: GAM10-02 Start Date*: 2006-03-28
    Sponsor Name:Octapharma AG
    Full Title: Clinical study to evaluate the efficacy and safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in adults.
    Medical condition: Idiopathic thrombocytopenic purpura, in adults actively bleeding or at high risk bleeding.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10021245 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-000263-27 Sponsor Protocol Number: IgPro10_4001 Start Date*: 2011-07-22
    Sponsor Name:CSL Behring LLC
    Full Title: An open-label, prospective, multicenter study to investigate the specificity of in vivo antibody binding to red blood cells in subjects with chronic immune thrombocytopenic purpura (ITP) treated wi...
    Medical condition: Chronic immune thrombocytopenic purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10005329 - Blood and lymphatic system disorders 10021245 Idiopathic thrombocytopenic purpura PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-016203-32 Sponsor Protocol Number: 20090340 Start Date*: 2009-11-19
    Sponsor Name:Amgen Inc
    Full Title: An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects with immune (Idiopathic) Thrombocytopenia Purpura (ITP).------------...
    Medical condition: Thrombocytopenia in pediatric subjects with ITP---------Sujetos Pediátricos Trombocitopénicos con Púrpura Trombocitopénica Inmune (Idiopática) (PTI)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10043558 Thrombocytopenia purpura LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-000537-11 Sponsor Protocol Number: ZLB03_003CR Start Date*: 2004-12-01
    Sponsor Name:ZLB Behring AG
    Full Title: An open-label, multicenter study on the efficacy and safety of IgPro10 in patients with chronic immune thrombocytopenic purpura (ITP)
    Medical condition: Immune thrombocytopenic purpura (ITP) is the most common autoimmune disease. It is a bleeding disorder characterized by decreased counts of circulating platelets and normal or increased numbers of ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000417-30 Sponsor Protocol Number: GIMEMA ITP0207 Start Date*: 2008-06-19
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: Randomized study for the treatment of primary Immune Thrombocytopenic Purpura (ITP) in newly diagnosed untreated adult patients. Comparison of standard dose prednisone versus high-dose Dexamethas...
    Medical condition: ITP Primary Immune Thrombocytopenic Purpura in newly diagnosed untreated adult patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003569-42 Sponsor Protocol Number: 20060195 Start Date*: 2007-09-29
    Sponsor Name:Amgen Inc.
    Full Title: Estudio Aleatorizado, Doble Ciego, Controlado con Placebo, de Fase 1/2 para Determinar la Seguridad y la Eficacia de AMG 531 en Sujetos Pediátricos Trombocitopénicos con Púrpura Trombocitopénica I...
    Medical condition: Púrpura Trombocitopénica Inmune (Idiopática) (PTI)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-010421-39 Sponsor Protocol Number: TRA112940 Start Date*: 2010-03-10
    Sponsor Name:GlaxoSmithKline
    Full Title: A longitudinal 2-year bone marrow study of eltrombopag olamine (SB-497115-GR) in previously treated adults, with chronic immune (idiopathic) thrombocytopenic purpura (ITP).
    Medical condition: Chronic Idiopathic Thrombocytopenic Purpura
    Disease: Version SOC Term Classification Code Term Level
    15.1 10005329 - Blood and lymphatic system disorders 10021245 Idiopathic thrombocytopenic purpura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FR (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003700-18 Sponsor Protocol Number: 20060131 Start Date*: 2007-02-05
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Controlled, Open- label Study Evaluating the Efficacy and Tolerability of AMG 531 versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects with Immune (Idiop...
    Medical condition: Immune (idiopathic) thrombocytopenic purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10021245 Idiopathic thrombocytopenic purpura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) FR (Completed) PT (Completed) CZ (Completed) BE (Completed) DE (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-001597-33 Sponsor Protocol Number: 20081203 Start Date*: 2009-06-18
    Sponsor Name:University Medical Center Utrecht
    Full Title: Development of chronic disease in newly diagnosed Idiopathic Thrombocytopenic Purpura of Childhood. A randomized controlled study on the influence of treatment with intravenous gammaglobulin on the...
    Medical condition: Acute Idiopathic Thrombocytopenic Purpura (ITP) in children
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10023095 ITP LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001503-23 Sponsor Protocol Number: ALX0681-C302 Start Date*: 2016-08-16
    Sponsor Name:Ablynx NV
    Full Title: Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
    Medical condition: Acquired thrombotic thrombocytopenic purpura (TTP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043648 Thrombotic thrombocytopenic purpura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) HU (Completed) GB (Completed) CZ (Completed) BE (Completed) FR (Completed) DE (Completed) NL (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006081-15 Sponsor Protocol Number: Sym001-03 Start Date*: 2008-05-20
    Sponsor Name:Symphogen A/S
    Full Title: A multi-centre, single intravenous dose, exploratory dose-finding, open label trial on the safety and efficacy of Sym001 in the treatment of Immune Thrombocytopenic Purpura (ITP) in RhD positive, n...
    Medical condition: Immune Thrombocytopenic Purpura (ITP) in RhD positive, non-splenectomized adult subjects
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043561 Thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) BE (Ongoing) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000796-16 Sponsor Protocol Number: GAMr-30 Start Date*: 2012-07-09
    Sponsor Name:OCTAPHARMA AG
    Full Title: PROSPECTIVE, OPEN-LABEL, NON-CONTROLLED, MULTICENTER, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCTAGAM 10% IN PRIMARY IMMUNE THROMBOCYTOPENIA
    Medical condition: Primary Immune Thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10023095 ITP LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004295-22 Sponsor Protocol Number: NL59645.098.16 Start Date*: 2017-04-10
    Sponsor Name:Hagaziekenhuis
    Full Title: Treatment of thromBocytopenia with EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients with Immune ThrombocytoPenia.
    Medical condition: Immune thrombocytopenia patients with low platelets and in need of surgery.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004851 10023095 ITP LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001354-29 Sponsor Protocol Number: I10E-0719 Start Date*: 2011-10-12
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: An open-label, multicentre efficacy and safety study of I10E in patients with primary Immune ThrombocytoPenia (ITP)
    Medical condition: ITP diagnosis being defined by ASH-2011 and BCSH 2010 criteria adopting the new consensus terminology proposed by an international working group (Rodeghiero et al, 2009)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004851 10023095 ITP LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2009-014589-24 Sponsor Protocol Number: NGAM-02 Start Date*: 2011-09-22
    Sponsor Name:Octapharma AG
    Full Title: Prospective, Open-label, Non-controlled, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NEWGAM) in Primary Immune Thrombocytopenia
    Medical condition: Primary Immune Thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10005329 - Blood and lymphatic system disorders 10023095 ITP LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) BG (Prematurely Ended) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:40:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA